6% or Equity
6% or Equity
Landcent is a global manufacturer and innovative developer of preventive healthcare products. Its mission is to accelerate the fight against malaria. It does this by developing affordable, sustainable solutions that can be safely used at scale.
Every year, more than 400 million people get sick from Malaria mosquitoes. More than 400,000 people succumb to it. This makes the Malaria mosquito the deadliest animal in the world. The majority (67%, or 268,000) are children under the age of 5! In other words, a child dies from a completely preventable disease, every 2 minutes. This is unacceptable to us who believe in the dignity of every human life. Although much progress had been made in fighting malaria, the number of cases has unfortunately increased again in the past 5 years. And due to the COVID-19 pandemic, the situation has even worsened. In addition to the fatal consequences of Malaria, many communities are also severely affected economically by the disease. In Africa alone, economic losses amount to about $12 billion a year.
Landcent was founded ten years ago in Shanghai, China. Its founders and largest shareholders are Christians. They are inspired by BAM (Business as Mission) principles.
‘Our goal is to work with fellow believers to bring the light of Christ to those places still affected by poverty and disease. We believe that disease prevention and elimination are a manifestation of God’s love and are part of our mission as Christians towards local communities.’ – Arun Prabhu, CEO and Co-Founder
Landcent understands that diseases such as malaria require short- and long-term approaches. The short-term strategy is to get the disease under control and mortality rates start to drop dramatically. With that in mind, Landcent wants to improve existing and proven prevention technologies and bring products to market that are affordable to broad segments of the population. With the same budget, millions more people should be able to be reached!
At the same time, Landcent is also working on the long-term strategy in order to thereby cope with resistance of the malaria mosquito in a timely manner. Research and development should lead to new products that are sustainable and safe to use on a large scale. We are contributing to the UN’s “Zero X 2040” initiative to eliminate Malaria worldwide by 2040.
Landcent is currently working on four products in three WHO-recommended Malaria control strategies. These four products are in various stages of development and include: Landcent Duo 2.0™ and Landcent Duo 3.0™ (new generation products of impregnated mosquito nets), Landcent DURUS CS™ (new product generation of Indoor Anti-Mosquito Spray) and Landcent CODISPAQ™ (new format chewable anti-malarial tablets that are especially designed for young children!).
The social impact of Landcent’s products in local communities in Africa is expected to be significant. The first products will be on the market as early as 2024. Within 4 years of market launch, our products will have helped prevent 182 Million (!) malaria infections and saved over 356,000 lives, including many children under the age of 5!
There is also expected to be a large financial impact because Landcent’s products, compared to existing products in the market, are many times more powerful and effective. Cost savings of 35% are to be expected. These are very welcome savings, especially for local governments that set up large prevention campaigns for their populations! An important impact is also that Landcent’s new antimalarial pill, CODISPAQ™, is not only inexpensive but also only needs to be taken very sparingly during the malaria season (4-5 months per year). Already with 4 tablets per month one is sufficiently protected. Such a low frequency is easily implemented by local governments through their prevention programs.
The Gates Foundation is also very enthusiastic about Landcent’s achievements! They support with donations especially the more risky long-term product developments. New malaria-resistant products should be available in 15 years. For the shorter-term product developments and the final phase towards market launch – with much more limited risks – we want to focus mainly on impact investments via private investors with like-minded values regarding their focus on social impact and stewardship. In the period 2021 – 2023, Landcent has a capital requirement of €10 million for the aforementioned short-term product development.
Join us and take advantage of this unique opportunity to make mission-oriented investments!
MissionInvest has committed through its network to realize €5 million for this extraordinary project, which will save so many lives! We are grateful that by the end of December 2022, over €1.65 of this has already been realized.
There are a number of opportunities for you as an investor to participate with tickets in the sizes of 200k, 500k and 1000k:
For investors who want to invest from a missionary standpoint and use their money to help solve a global problem, Landcent is a wonderful proposition!
Please note! Your investments are not subject to the supervision of the Dutch Authority for the Financial Markets (AFM). There is no permit and prospectus requirement for this activity.